Australia markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1600+0.0200 (+0.64%)
As of 01:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.1400
Bid3.1600 x 1800
Ask3.1700 x 1300
Day's range3.1000 - 3.2400
52-week range2.8700 - 8.5800
Avg. volume4,248,921
Market cap325.237M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-5.6700
Earnings date08 May 2023 - 12 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.80
  • Motley Fool

    Why Bluebird Bio Stock Is Sinking This Week

    Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.

  • Zacks

    Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

    SOMERVILLE, Mass., March 29, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates.